8Vc Gp I LLC Sells 977,570 Shares of BiomX Inc. (NYSEMKT:PHGE)

8Vc Gp I LLC trimmed its stake in shares of BiomX Inc. (NYSEMKT:PHGE) by 90.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,621 shares of the company’s stock after selling 977,570 shares during the quarter. BiomX comprises approximately 0.2% of 8Vc Gp I LLC’s investment portfolio, making the stock its 3rd biggest position. 8Vc Gp I LLC owned about 0.61% of BiomX worth $111,000 as of its most recent SEC filing.

Separately, Ikarian Capital LLC bought a new stake in BiomX during the first quarter worth about $4,868,000. 40.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of BiomX in a research note on Friday, August 16th.

BiomX Trading Down 17.3 %

PHGE opened at $0.62 on Monday. The stock has a market capitalization of $11.10 million, a P/E ratio of -0.19 and a beta of 1.31. The business has a 50 day moving average of $0.92 and a 200-day moving average of $2.15. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.